Cases & Deals

Share

Bayer AG acquires Icon Genetics

January 2006

Client(s) Bayer AG

Jones Day advised Bayer AG in the acquisition by its subsidiary Bayer Innovation GmbH of Icon Genetics AG from its founders and certain mostly state-owned venture capital funds. Icon Genetics discovers innovative methods for the development and use of engineered plants. Bayer Innovation evaluates and develops new fields of business for the Bayer Group that are in line with Bayer's core competencies of health care, nutrition and high-tech materials and complement its current key areas of innovation and business. Bayer and Icon Genetics had already cooperated on research projects prior to the transaction.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.